staurosporine has been researched along with h 1152 in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bonn, S; Bossemeyer, D; Breitenlechner, CB; Engh, RA; Erlbruch, A; Gassel, M; Herrero, S; Lehmann, W | 1 |
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW | 1 |
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
Doddareddy, MR; Kassiou, M; Kavanagh, ME | 1 |
4 other study(ies) available for staurosporine and h 1152
Article | Year |
---|---|
Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
Topics: Animals; Benzamides; Cattle; Cyclic AMP-Dependent Protein Kinases; Erlotinib Hydrochloride; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Models, Molecular; Mutagenesis, Site-Directed; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; rho-Associated Kinases; Structure-Activity Relationship; Substrate Specificity | 2006 |
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin | 2007 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
Topics: Central Nervous System; Central Nervous System Agents; Dose-Response Relationship, Drug; Drug Discovery; High-Throughput Screening Assays; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Molecular Structure; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Structure-Activity Relationship | 2013 |